BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24203085)

  • 1. Use of bisphosphonates and the risk of osteonecrosis among cancer patients: a systemic review and meta-analysis of the observational studies.
    Lee SH; Chan RC; Chang SS; Tan YL; Chang KH; Lee MC; Chang HE; Lee CC
    Support Care Cancer; 2014 Feb; 22(2):553-60. PubMed ID: 24203085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis.
    Lee SH; Chang SS; Lee M; Chan RC; Lee CC
    Osteoporos Int; 2014 Mar; 25(3):1131-9. PubMed ID: 24343364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures.
    Lapi F; Cipriani F; Caputi AP; Corrao G; Vaccheri A; Sturkenboom MC; Di Bari M; Gregori D; Carle F; Staniscia T; Vestri A; Brandi M; Fusco V; Campisi G; Mazzaglia G;
    Osteoporos Int; 2013 Feb; 24(2):697-705. PubMed ID: 22618266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study.
    Wessel JH; Dodson TB; Zavras AI
    J Oral Maxillofac Surg; 2008 Apr; 66(4):625-31. PubMed ID: 18355585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people.
    Cartsos VM; Zhu S; Zavras AI
    J Am Dent Assoc; 2008 Jan; 139(1):23-30. PubMed ID: 18167381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis.
    Everts-Graber J; Lehmann D; Burkard JP; Schaller B; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
    J Bone Miner Res; 2022 Feb; 37(2):340-348. PubMed ID: 34787342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis.
    Zhang C; Shen G; Li H; Xin Y; Shi M; Zheng Y; Wang M; Liu Z; Zhao Y; Zhao F; Ren D; Zhao J
    Spec Care Dentist; 2024; 44(2):530-541. PubMed ID: 37219080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The increase in prescriptions of bisphosphonates and the incidence proportion of osteonecrosis of the jaw after risk communication activities in Japan: a hospital-based cohort study.
    Sumi E; Yamazaki T; Tanaka S; Yamamoto K; Nakayama T; Bessho K; Yokode M
    Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):398-405. PubMed ID: 24399628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study.
    Fung P; Bedogni G; Bedogni A; Petrie A; Porter S; Campisi G; Bagan J; Fusco V; Saia G; Acham S; Musto P; Petrucci MT; Diz P; Colella G; Mignogna MD; Pentenero M; Arduino P; Lodi G; Maiorana C; Manfredi M; Hallberg P; Wadelius M; Takaoka K; Leung YY; Bonacina R; Schiødt M; Lakatos P; Taylor T; De Riu G; Favini G; Rogers SN; Pirmohamed M; Nicoletti P; ; Fedele S
    Oral Dis; 2017 May; 23(4):477-483. PubMed ID: 28039941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy.
    Fleisher KE; Jolly A; Venkata UD; Norman RG; Saxena D; Glickman RS
    J Oral Maxillofac Surg; 2013 Mar; 71(3):513-9. PubMed ID: 22999296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan.
    Liu FC; Luk KC; Chen YC
    Osteoporos Int; 2023 Oct; 34(10):1729-1737. PubMed ID: 37326685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
    Khan AA; Morrison A; Kendler DL; Rizzoli R; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Dabagh RA; Davison KS; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J;
    J Clin Densitom; 2017; 20(1):8-24. PubMed ID: 27956123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of 225 patients on bisphosphonates presenting to the bisphosphonate clinic at King's College Hospital.
    Taylor T; Bryant C; Popat S
    Br Dent J; 2013 Apr; 214(7):E18. PubMed ID: 23579162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
    Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
    Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE; Umland EM
    Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bisphosphonates and osteonecrosis of the jaws].
    Urade M
    Clin Calcium; 2007 Feb; 17(2):241-8. PubMed ID: 17272882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons.
    Khan AA; Rios LP; Sándor GK; Khan N; Peters E; Rahman MO; Clokie CM; Dore E; Dubois S
    J Rheumatol; 2011 Jul; 38(7):1396-402. PubMed ID: 21498483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The national-scale cohort study on bisphosphonate-related osteonecrosis of the jaw in Taiwan.
    Yuh DY; Chang TH; Huang RY; Chien WC; Lin FG; Fu E
    J Dent; 2014 Oct; 42(10):1343-52. PubMed ID: 24907558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
    Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ
    J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.